Concepedia

Author

Frede Donskov

Aarhus University HospitalORCID

Also Known As

Donskov F, Donskov, F., Donskov, Frede, F Donskov, F. Donskov, Frede Donskov, Frede N. Donskov, Suen, DTK, Vries, Heinde

369

Publications

28.8K

Citations

62

H-Index

100

Concepts

All Affiliations

Aarhus University HospitalDana-Farber Cancer InstituteCleveland ClinicUniversity of CalgaryHarvard University
FD

About

Frede Donskov is an author at Aarhus University Hospital specializing in medicine, oncology, and urology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

39

84

8.9K

2

Health Sciences

16

25

877

3

Engineering

1

1

12

4

Public Health

1

1

11

5

Biostatistics

1

1

1K

Frede Donskov

×

163

Publications

27.5K

Citations

60

H-Index

YearCitations

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Bernard Escudier, Saby George,

New England Journal of Medicine

2015

5.8K

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Nizar M. Tannir, Osvaldo Arén Frontera,

New England Journal of Medicine

2018

4.5K

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Bernard Escudier, Thomas Powles,

New England Journal of Medicine

2015

1.2K

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan,

The Lancet Oncology

2013

1K

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Brian I. Rini, Thomas Powles, Michael B. Atkins,

The Lancet

2019

988

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Toni K. Choueiri, Bernard Escudier, Thomas Powles,

The Lancet Oncology

2016

927

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Robert J. Motzer, Brian I. Rini, David F. McDermott,

The Lancet Oncology

2019

763

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

Alain Ravaud, Robert J. Motzer, Hardev Pandha,

New England Journal of Medicine

2016

757

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

Laurence Albigès, Nizar M. Tannir, Mauricio Burotto,

ESMO Open

2020

515

Presence of Intratumoral Neutrophils Is an Independent Prognostic Factor in Localized Renal Cell Carcinoma

Hanne Krogh Jensen, Frede Donskov, Niels Marcussen,

Journal of Clinical Oncology

2009

468

Page 1